DB818 is an inhibitor of the AML driving HOXA9, which led to growth inhibition and apoptosis induction in HOXA9-overexpressing OCI/AML3, MV4-11, and THP-1 AML cells by suppression of MYB, MYC, and BCL2[216]. Here, BCL2 is linked to acute myeloid leukemia.